Business Wire

KUBESPHERE

27.5.2021 09:50:06 CEST | Business Wire | Press release

Share
Managing Kubernetes at the Edge: KubeSphere Container Platform 3.1 General Availability

KubeSphere Community announced the general availability of KubeSphere v3.1.0. KubeSphere, as an app-centric distributed operating system running on top of Kubernetes, has further expanded its portfolio to deliver more robust experiences for users across the globe, enabling DevOps teams to run Kubernetes workloads where and when they want with ease and security.

“KubeSphere has emerged as one of the most popular Kubernetes platforms ,” said Ray Zhou, Head of the KubeSphere project. “The release of KubeSphere 3.1 marks an important milestone as we further empower enterprises to gain first-mover advantages especially in edge computing.”

Taking Kubernetes From Hybrid Multi-Cloud to Edge

KubeSphere v3.1.0 provides an enabling environment for users as they can deploy production workloads not just across clouds but also at the edge . Besides, the new Metering and Billing function helps IT administrators better understand infrastructure operating costs. Existing features of multi-cluster management , multi-tenant management, observability, DevOps, application lifecycle management , and microservices governance have also been enhanced to ensure better user experiences across clusters and clouds .

Major updates include:

  • Metering and billing to track infrastructure cost
  • Edge node management for orchestrating apps and edge devices
  • Lightweight Kubernetes multi-cloud and multi-cluster management
  • Unified Kubernetes monitoring in one dashboard
  • Easier Kubernetes installation
  • Enhanced security with authentication and multi-tenancy

A full list of new features can be found in Release Note 3.1.0 . For a detailed introduction and interpretation, check out the latest KubeSphere 3.1.0 announcement

Commitment to Open-Source and Community

KubeSphere is making great strides on its international journey with over 100,000 downloads across 90 countries and regions to date. The KubeSphere console currently supports four official languages - English, Simplified Chinese, Traditional Chinese and Spanish.

“When you take a step back and reflect on how far KubeSphere has come, it is not surprising to find that it has become one of the most widely used container platforms not just in our country, but also around the world,” Ray added. “Our contributors from all corners of the world have shown us what open source is all about. And this is exactly what has been driving us to push the limits of what’s possible with Kubernetes.”

KubeSphere v3.1.0 remains committed to fully open source with an ever-expanding ecosystem, also helps developers to deploy code with several clicks on the friendly console, and brings integrated observability and powerful Kubernetes DevOps strategies for the Ops team.

About KubeSphere

KubeSphere is an open-source container platform based on Kubernetes. It provides full-stack IT automated operation and streamlined DevOps workflows. KubeSphere offers wizard web UI and enterprise-grade features for operation and maintenance, including multi-cloud and multi-cluster management , DevOps (CI/CD ), application lifecycle management , service mesh , multi-tenant , observability ,storage and network , and GPU support .

For more information, visit website https://kubesphere.io , GitHub https://github.com/kubesphere/kubesphere and follow @KubeSphere on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye